Regeneron Pharmaceuticals (REGN) is the biotech jungle’s clever monkey, swinging at $730.30 (U.S. News) with a $103 billion market cap as of March 26, 2025. This Tarrytown trickster’s got Dupixent, Eylea, and a pipeline full of brainy bets—time to grab this stock or fling it back?
Let’s monkey around with the perks. Regeneron’s a cash-slinging champ—Dupixent (with Sanofi) treats everything from asthma to COPD, pulling in $11 billion yearly. Eylea HD and Libtayo are eye and cancer stars, and linvoseltamab’s eyeing FDA approval for multiple myeloma by mid-2025 (Motley Fool’s jazzed). Argus pegs it at $1,000—a 37% vault—calling it a “Buy,” while TipRanks’ 16 Buy ratings scream “Strong Buy.” At 23x forward earnings, it’s a steal for a growth monkey. X chatter’s bananas—“Regeneron’s a genius factory!”—and with 13 late-stage programs, it’s swinging high.
But watch for slippery branches. Tariffs (25% on Canada/Mexico, 10% on China) could jack up costs—those lab monkeys need imported gear. The market’s twitchy—S&P 500’s down 1.78% YTD—and if Dupixent’s growth slips, it’s a long fall. Picture this: you’re swinging through the treetops, wind in your fur, but a storm’s brewing. One X user chirped, “Too pricey for slow growth”—a fair screech if you’re chasing rocket rides over steady climbs.
Fun fact: Regeneron’s founder once raced mice to study genetics—talk about a brainy origin story! Today, it’s less rodents, more riches, with $7 billion in cash to fund its antics. The Fed’s pause and economic fog (LEI down 0.3%) might rattle the canopy, but Regeneron’s balance sheet’s a sturdy branch. Buy, and you’re swinging with a clever primate; sell, and you’re bailing before a potential slip.
Verdict: Buy for the brainy gains; sell if you fear a tariff tumble.
Disclaimer: Consult a financial advisor before monkeying with this stock!
